#Israel #Tel Aviv #LUT014 #Gefitinib #Anti-Cancer

Lutris Pharma Presents Positive Data From Phase 2 Trial of LUT014 Gel

Overview

Lutris Pharma has recently unveiled positive updated results from its Phase 2 trial involving LUT014 Gel, a novel treatment aimed at addressing dermatological toxicities linked to EGFR inhibitors. This significant announcement was made at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, which took place from September 30 to October 3, 2026. The results signify a promising advance in the treatment of EGFRI-induced acneiform rash, a common side effect faced by cancer patients undergoing anti-cancer therapy.

Background

LUT014 is a proprietary topical B-Raf inhibitor specifically formulated to alleviate skin-related issues caused by anti-cancer treatments affecting the MAPK pathway. Those undergoing anti-cancer therapies may suffer from various dermatological side effects, including acneiform rashes, which can significantly diminish their quality of life and lead to reduced drug adherence.

Key Findings

The trial's outcomes showed that the 0.1% concentration of LUT014 Gel led to a notable improvement in treatment success rates, with 71.8% of patients achieving this benchmark compared to only 38.5% in the placebo group (p=0.003). Furthermore, clinicians reported a significant reduction in rash severity amongst those treated with LUT014, with 56.4% experiencing a one-grade improvement compared to 15.4% of those on placebo (p=0.0002).

Patient feedback also showed an improvement, with 53.8% reporting at least a five-grade enhancement in their symptoms versus 28.2% in the placebo cohort (p=0.021). These effects maintained durability beyond the initial 28-day treatment period, as evidenced by 69.2% of LUT014 patients achieving treatment success by Day 55 against 31.8% in the placebo arm (p=0.005).

Equally significant is that non-adherence due to treatment side effects was far lower among LUT014 patients (10.3%) compared to those who received the placebo (28.2%) (p=0.044). This data affirms LUT014's potential in promoting adherence to prescribed EGFR-directed therapies, thereby supporting better patient outcomes.

Implications of Findings

The results, as explained by Dr. Anisha Patel, a professor of dermatology at MD Anderson Cancer Center, highlight how EGFRI-induced acneiform rash can severely impact patients, prompting dose reductions and treatment discontinuation. The favourable findings of LUT014 present an opportunity for patients to continue their therapy while experiencing meaningful symptomatic relief.

Professor Antoni Ribas, co-founder of Lutris Pharma, stated that they are excited about the implications of LUT014's efficacy, safety, and tolerability and are planning further studies involving the product in treating acneiform rash induced by daraxonrasib in pancreatic ductal adenocarcinoma patients. This shows the versatility and potential of LUT014 across a spectrum of MAPK-pathway inhibitors.

Study Design

The successful trial involved 118 adult patients diagnosed with colorectal cancer (CRC) who developed EGFRI-induced acneiform lesions. Participants were randomly assigned to receive either LUT014 0.1%, LUT014 0.03%, or placebo gel, applied once daily for 28 days. Treatment success was assessed based on improvements in established clinical measures.

Conclusion

As Lutris Pharma continues to explore opportunities to partner and expand the applicability of LUT014, this updated Phase 2 data reinforces the potential impact of the gel on the lives of cancer patients grappling with the burdensome side effects of their therapies. The 35th EADV Congress served as a pivotal platform for these promising findings, which could lead to future advancements in patient care and treatment adherence.

For further information about Lutris Pharma and its innovative treatments, visit Lutris Pharma's website.